Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arvinas Inc ARVN

Healthcare
Arvinas, Inc. is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The Company uses its PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein... see more

Recent & Breaking News (NDAQ:ARVN)

Arvinas Appoints Kelly Page as Senior Vice President, Global Head of Oncology Strategy and Program Leadership

GlobeNewswire April 3, 2023

Arvinas to Participate in Upcoming Investor Conferences

GlobeNewswire February 27, 2023

Arvinas Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

GlobeNewswire February 23, 2023

Arvinas to Participate in Upcoming Investor Conferences

GlobeNewswire February 6, 2023

Arvinas to Present at 41st Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 4, 2023

Arvinas Announces Changes to its Board of Directors

GlobeNewswire December 16, 2022

Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)

GlobeNewswire November 22, 2022

Arvinas Reports Third Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire November 8, 2022

Arvinas to Present at Upcoming Conferences

GlobeNewswire November 1, 2022

Arvinas Announces Winner of the 2022 Arvinas Early Career Researcher Award

GlobeNewswire October 27, 2022

Arvinas Appoints Paul McInulty as Senior Vice President, Regulatory Affairs

GlobeNewswire October 3, 2022

Arvinas Gives Back to Local Greater New Haven Community

GlobeNewswire September 30, 2022

Arvinas to Present at Bank of America Securities Precision Oncology Conference

GlobeNewswire September 26, 2022

Arvinas to Present at Upcoming Investor Conferences

GlobeNewswire August 31, 2022

Arvinas Announces Changes to its Board of Directors

GlobeNewswire August 18, 2022

Arvinas Appoints Lisa Sinclair as Senior Vice President, Corporate Operations

GlobeNewswire August 15, 2022

Arvinas Reports Second Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire August 4, 2022

Arvinas Appoints John Northcott as Chief Commercial Officer

GlobeNewswire August 1, 2022

Arvinas to Present at Goldman Sachs 43rd Annual Global Healthcare Conference

GlobeNewswire June 2, 2022

Arvinas Launches Global Early Career Researcher Award and Announces Call for Nominations

GlobeNewswire June 1, 2022